Journal
ONCOIMMUNOLOGY
Volume 1, Issue 5, Pages 773-776Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.19729
Keywords
drug-resistance; interferon-alpha; immunotherapy; targeted therapy; imatinib; peginterferon alpha-2b; gastrointestinal stromal tumor
Categories
Funding
- NCRR NIH HHS [UL1 RR024148] Funding Source: Medline
Ask authors/readers for more resources
Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is, 2 y. B-RAF(V600)-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is, 9 mo. Combining imatinib with immunotherapy (peginterferon alpha-2b) in GIST showed significant induction of antitumor immunity and highly promising clinical outcomes. This strategy warrants further testing in other malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available